3 07 June 2021 Semaglutide 2.4 mg approval in the US Strategic aspirations 2025 • Being respected for adding value to society • Progress towards zero environmental impact • Ensure distinct core capabilities and evolve culture • Strengthen Diabetes leadership - aim at global value market share of more than 1/3 • Strengthen Obesity leadership and double current sales 1 • Secure a sustained growth outlook for Biopharm 1 Based on reported sales in 2019, 2 From 2015 to 2022, 70% of sales to come from products launched from 2015. IO: Int
Download PDF file